Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ DOK1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA599555
Description
Antibody detects endogenous levels of total p62 Dok.
DOK1 (P62dok, Docking protein 1) is believed to be a mainly cytoplasmic adaptor protein which down-regulates mitogen-activated protein kinase activation, inhibits cell proliferation and transformation, and promotes cell spreading and cell migration. DOK1 is a major substrate for many tyrosine kinases including c-kit, v-abl, vFPS, EGF, and PDGF. Upon phosphorylation by kinases, DOK1 forms a complex with ras GTPase-activating protein. Phosphorylation on tyrosine residues by the insulin receptor kinase results in the negative regulation of the insulin signaling pathway. DOK1 contains a putative pleckstrin homology domain at the amino terminus and ten PXXP SH3 recognition motifs.
Specifications
DOK1 | |
Polyclonal | |
Unconjugated | |
DOK1 | |
AW557123; Docking protein 1; docking protein 1, 62kDa (downstream of tyrosine kinase 1); Dok; DOK 1; DOK1; Dok-1; Downstream of tyrosine kinase 1; downstream of tyrosine kinase-1; MGC117395; MGC138860; p240; p62 dok; p62(dok); p62DOK; pp62; TLP1; TP1; TROVE domain family; TROVE1; VAULT2 | |
Rabbit | |
Affinity chromatography | |
RUO | |
13448, 1796, 312477 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
P97465, Q4QQV2, Q99704 | |
DOK1 | |
A synthesized peptide derived from human DOK1(Accession Q99704), corresponding to amino acid residues P372-A422. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction